Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Considerations and Collaboration

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Administration and Management

Interview with Danielle Roberts, PA-C: Sequencing of Bispecific Antibodies and CAR T-Cell Therapies

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

Make it Happen: To Better Serve the Multiple Myeloma Community

Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management

Dietary and Microbiome Evidence in Multiple Myeloma and Other Plasma Cell Disorders

Ethical Challenges in CAR-T Slot Allocation

A Focus on Relapsed Multiple Myeloma

Cancer Reports

Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

Clinical Lymphoma, Myeloma & Leukemia

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

Transfusion Clinique et Biologique

Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

Multiple Myeloma Resource Center

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Considerations and Collaboration

Make it Happen: To Better Serve the Multiple Myeloma Community

Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management

Dietary and Microbiome Evidence in Multiple Myeloma and Other Plasma Cell Disorders

Ethical Challenges in CAR-T Slot Allocation

A Focus on Relapsed Multiple Myeloma

Cancer Reports

Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

Clinical Lymphoma, Myeloma & Leukemia

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

Transfusion Clinique et Biologique

Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

Treatment of Intermediate Risk Smoldering Myeloma

Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy

Single Solitary Plasmacytoma to Active Myeloma